Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatocellular carcinoma
(
HCC
) is becoming one of the common malignant tumors worldwide and is characterized by high vascularity. Angiogenesis (formation of new microvessels) is critical for growth and progression of various human solid tumors. Betacellulin (BTC) is a member of the epidermal growth factor (EGF) family, and its signal action is mediated through EGF receptors (EGFR). In this study, to understand the role of BTC in relation to EGFR in
HCC
, we examined localization, expression, and involvement in angiogenesis of BTC and EGFR. The results revealed that expression of BTC, EGFR, and tumor growth factor-alpha messenger RNA in
HCC
was increased by 80%, 60%, and 40%, respectively, as compared with those in the nontumorous tissues. Increased expression of
BTC protein
was observed in 31 (61%) of 51
HCC
specimens, and the level of tumor growth factor-alpha protein was higher in 17 (33%) of 51
HCC
specimens than in nonmalignant hepatocytes. Betacellulin was predominantly expressed in
HCC
cells, whereas EGFR was observed in sinusoidal endothelial cells of
HCC
in 25 tumors (49%). Betacellulin was secreted in all 4 examined
HCC
cell lines. The
HCC
specimens showing positive EGFR expression in tumor endothelial cells had a significantly higher microvessel density than those without EGFR expression (P < .005). A strong correlation was found between BTC expression in cancer cells and EGFR expression in tumor endothelial cells (P < .001). These findings suggest that overexpression of BTC by
HCC
cells and EGFR by tumor endothelial cells enhance vascularity in a paracrine manner.
...
PMID:Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. 1694 29